Quintiles deepens investment in China
Quintiles has decided to establish a Quintiles regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China.
“With its burgeoning economy and growing healthcare needs for its 1.3 billion citizens, China exemplifies the opportunities and challenges of the New Health,” said Quintiles executive chairman Dennis Gillings, CBE. “By broadening our investment and infrastructure here, Quintiles is ready to partner with our biopharma customers as they look to realize China’s potential.”
To provide the infrastructure essential for its growth strategy in China, Quintiles is investing $14 million to establish a new 4,000-square-meter (43,000 square feet) headquarters in Shanghai to serve China and nearby Asian countries. The office in Feng Lin Science Park is designed to achieve LEED Gold accreditation; it is expected to accommodate more than 450 employees in the next five years.
Quintiles will also engage the Shanghai Clinical Research Centre (SCRC) to provide lab testing services to local customers.
“Quintiles recognizes the unique needs of our customers in China. By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China’s enormous unmet medical needs,” said Ling Zhen, general manager for Quintiles’ operations in China.
The Quintiles-SCRC collaboration follows last year’s launch of Kun Tuo, Quintiles’ local CRO, built to help local and global biopharma companies achieve successful registration of medicines in China. Quintiles commenced operations in China in 1997, and today has offices in Beijing, Dalian, Hong Kong and Shanghai, with employees and capabilities to serve all major population centers and study sites across China.